CytoDyn Inc. (CYDY)

OTCMKTS: CYDY · Delayed Price · USD
0.250
0.00 (0.00%)
Jan 13, 2023, 3:59 PM EST - Market closed
Market Cap 208.24M
Revenue (ttm) 41,000
Net Income (ttm) -190.76M
Shares Out 832.97M
EPS (ttm) -0.32
PE Ratio n/a
Forward PE 10.81
Dividend n/a
Ex-Dividend Date n/a
Volume 1,846,855
Open 0.255
Previous Close 0.250
Day's Range 0.243 - 0.260
52-Week Range 0.150 - 1.260
Beta 0.16
Analysts Sell
Price Target n/a
Earnings Date Jan 9, 2023

About CYDY

CytoDyn Inc. operates as a clinical-stage biotechnology company. The company focuses on developing treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor in the areas of human immunodeficiency virus (HIV), non-alcoholic steatohepatitis (NASH), oncology, and such as coronavirus disease (“COVID-19”). It is also conducting a Phase 1b/2 clinical trial with leronlimab in metastatic triple-negative breast cancer. The company was formerly known as RexRay Corporation. CytoD... [Read more]

Industry Biotechnology
Sector Healthcare
CEO Dr. Nitya G. Ray Ph.D.
Employees 23
Stock Exchange OTCMKTS
Ticker Symbol CYDY
Full Company Profile

Financial Performance

Financial Statements

News

CytoDyn to Hold Webcast to Discuss the Performance of Leronlimab in Clinical Trials and Recent Charges Against Former CEO

VANCOUVER, Washington, Dec. 23, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential fo...

1 month ago - GlobeNewsWire

Former CytoDyn CEO and clinical trial associate indicted for defrauding investors

The U.S. Department of Justice will prosecute the former CEO of Vancouver, Wash.-based biotech company CytoDyn, Nader Pourhassan, and an associate for allegedly defrauding investors.

1 month ago - GeekWire

CytoDyn to Host R&D Update on Wednesday, December 7, 2022

VANCOUVER, Washington, Nov. 22, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential fo...

2 months ago - GlobeNewsWire

CytoDyn Announces Voluntary Withdrawal of BLA for HIV-MDR Due to CRO Data Management Issues

Company to complete and submit responses to FDA clinical hold

3 months ago - GlobeNewsWire

CytoDyn Announces Appointment of Additional Directors with Industry Experience

Stephen Simes career public biotech company CEO and Ryan Dunlap CFO with public biotech company experience join Board

3 months ago - GlobeNewsWire

CytoDyn to Hold Webcast to Provide a Quarterly Company Update

VANCOUVER, Washington, Sept. 19, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential f...

4 months ago - GlobeNewsWire

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CytoDyn Inc. - CYDY

New York, New York--(Newsfile Corp. - August 12, 2022) - Pomerantz LLP is investigating claims on behalf of investors of CytoDyn Inc. ("CytoDyn" or the "Company") (OTCQB: CYDY). Such investors are adv...

6 months ago - Newsfile Corp

CYTODYN ALERT: Bragar Eagel & Squire, P.C. is Investigating CytoDyn, Inc. on Behalf of CytoDyn Stockholders and Encourages Investors to Contact the Firm

NEW YORK--(BUSINESS WIRE)-- #Action--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against CytoDyn, Inc. (“CytoDyn” or the “Compan...

6 months ago - Business Wire

CytoDyn Appoints Cyrus Arman, Ph.D., MBA, as President

VANCOUVER, Washington, July 13, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential fo...

7 months ago - GlobeNewsWire

CytoDyn Highlights NIH Grant for HIV Functional Cure Preclinical Study of Gene Therapy Based on Leronlimab

$5 Million Grant Awarded to OHSU for Preclinical Research of One-time Injection of Gene Therapy Based on Leronlimab for Functional Cure of HIV

7 months ago - GlobeNewsWire

CytoDyn Announces Resolution of Legal Dispute with Former Chief Medical Officer

VANCOUVER, Washington, May 23, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for...

9 months ago - GlobeNewsWire

CytoDyn Announces the Addition of Leading Experts in Oncology, Infectious Diseases, and Neuroinflammation to its Scientific Board of Advisors; Dr. Jay Lalezari to Serve as Outside Scientific Advisor

VANCOUVER, Washington, May 13, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for...

9 months ago - GlobeNewsWire

CytoDyn Announces Publication of Peer-Reviewed Paper, “Suppression of Human and Simian Immunodeficiency Virus Replication with the CCR5-Specific Antibody Leronlimab in Two Species”

VANCOUVER, Washington, April 12, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the ...

10 months ago - GlobeNewsWire

CytoDyn Announces Partial Clinical Hold of HIV Program and Full Clinical Hold of COVID-19 Program

Live webcast to be held March 31 discussing announcement

10 months ago - GlobeNewsWire

CytoDyn to Hold Webcast to Provide Company Update

VANCOUVER, Washington, March 30, 2022 (GLOBE NEWSWIRE) --  CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the...

10 months ago - GlobeNewsWire

CytoDyn's stock falls 4% after getting warning letter from FDA about experimental COVID-19 treatment

Shares of CytoDyn Inc. CYDY, -4.11% fell 4.9% in trading on Tuesday, the same day that the Food and Drug Administration issued a warning letter to the company over a video that features the former CEO...

1 year ago - Market Watch

CytoDyn CEO ousted after year of lawsuits, FDA rebuke, and ongoing investigations

Nader Pourhassan has been ousted as CEO and president by the board of directors of embattled Vancouver, Wash.

1 year ago - GeekWire

CytoDyn Announces Leadership Transition Plan to Support Regulatory Approval and Commercialization of Leronlimab

VANCOUVER, Wash.--(BUSINESS WIRE)--Today the Board of Directors (“the Board”) of CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagoni...

1 year ago - Business Wire

CytoDyn Cancels Webcast and Live Q/A Scheduled for Today

VANCOUVER, Wash.--(BUSINESS WIRE)--CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple ...

1 year ago - Business Wire

CytoDyn to Hold Webcast and Live Q/A on January 13

VANCOUVER, Washington, Jan. 11, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the p...

1 year ago - GlobeNewsWire

Regnum Signs Assignment and Assumption Agreement with CytoDyn and SevenScore Pharmaceuticals to Commercialize Leronlimab in the U.S. for the Treatment of HIV

NEW YORK, Jan. 10, 2022 /PRNewswire/ -- Regnum Corp. (OTCMKT: RGMP) ("Regnum"), CytoDyn Inc. (OTC.QB: CYDY) ("CytoDyn"), and SevenScore Pharmaceuticals, LLC ("SevenScore"), today announced the assignm...

1 year ago - PRNewsWire

CytoDyn Announces Favorable Ruling Granting Injunction Against Former CRO

VANCOUVER, Wash.--(BUSINESS WIRE)--CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple ...

1 year ago - Business Wire

CytoDyn Receives Positive Response From FDA in Regard to its Phase 3, Registrational Trial in COVID-19 Critically Ill Population

VANCOUVER, Wash.--(BUSINESS WIRE)--CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple ...

1 year ago - Business Wire

CytoDyn to Hold Webcast and Live Q/A on December 14

VANCOUVER, Washington, Dec. 10, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the p...

1 year ago - GlobeNewsWire

CytoDyn Submits Protocol with the FDA for Phase 3 Registrational Trial of Leronlimab for Critically Ill COVID-19 Population

VANCOUVER, Washington--(BUSINESS WIRE)--CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for mult...

1 year ago - Business Wire